4.5 Article

Objective Definition and Optimized Strategy for Biologically Borderline Resectable Colorectal Liver Metastases

Related references

Note: Only part of the references are listed.
Article Oncology

Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial

Eva Versteijne et al.

Summary: This study investigates the impact of neoadjuvant chemoradiotherapy on the survival of patients with resectable and borderline resectable pancreatic cancer. The results demonstrate that neoadjuvant chemoradiotherapy improves overall survival compared to upfront surgery in these patients.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Article Oncology

Chemotherapy in patients with a solitary colorectal liver metastasis - A nationwide propensity score matched study

P. Fruhling et al.

Summary: This nationwide register-based study found no difference in overall survival between patients treated with chemotherapy and those treated with surgery alone in cases of solitary colorectal liver metastasis. Upfront surgery may be preferable for resectable cases of solitary colorectal liver metastasis.
Article Surgery

Impact of tumor burden score on timing and patterns of recurrence after curative-intent resection of hepatocellular carcinoma

Zorays Moazzam et al.

Summary: This study aimed to identify factors associated with the risk and timing of recurrence after resection of hepatocellular carcinoma based on differences in tumor burden score. The results showed that tumor burden score was independently associated with a higher risk of recurrence. Patients with a high tumor burden score were more likely to experience early recurrence with multiple tumors and at an extrahepatic site. Tumor burden score is an important tool in assessing the risk, timing, and pattern of recurrence after resection of hepatocellular carcinoma.

SURGERY (2022)

Article Surgery

Recurrence at surgical margin following hepatectomy for colorectal liver metastases is not associated with R1 resection and does not impact survival

Andreas Andreou et al.

Summary: This study showed that positive resection margins did not affect the occurrence of hepatic local recurrence after hepatectomy for colorectal liver metastases. Additionally, hepatic local recurrence at the resection margin did not have a significant impact on overall survival compared to recurrence at other sites. Therefore, R1 status at hepatectomy may be more indicative of disease progression rather than worse prognosis.

SURGERY (2021)

Article Oncology

Primary Tumor Resection Plus Chemotherapy Versus Chemotherapy Alone for Colorectal Cancer Patients With Asymptomatic, Synchronous Unresectable Metastases (JCOG1007; iPACS): A Randomized Clinical Trial

Yukihide Kanemitsu et al.

Summary: This study investigated whether primary tumor resection (PTR) before chemotherapy improves survival in patients with colorectal cancer (CRC) with asymptomatic primary tumor and synchronous unresectable metastases. The results showed that PTR followed by chemotherapy did not provide a survival benefit over chemotherapy alone for CRC patients with asymptomatic primary tumors and synchronous unresectable metastases.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Article Oncology

Association between imaging response and survival following neoadjuvant chemotherapy in patients with resectable colorectal liver metastases: A cohort study

C. Behrenbruch et al.

Summary: This study did not find convincing evidence of an association between the imaging response to neoadjuvant chemotherapy and survival following colorectal liver metastasis resection.

JOURNAL OF SURGICAL ONCOLOGY (2021)

Article Oncology

Hepatectomy Followed by mFOLFOX6 Versus Hepatectomy Alone for Liver-Only Metastatic Colorectal Cancer (JCOG0603): A Phase II or III Randomized Controlled Trial

Yukihide Kanemitsu et al.

Summary: Adjuvant mFOLFOX6 chemotherapy after hepatectomy significantly improves disease-free survival (DFS) in liver-only metastatic colorectal cancer patients compared to hepatectomy alone. However, the impact of chemotherapy on overall survival (OS) remains unclear.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Article Oncology

Pancreatic Adenocarcinoma, Version 2.2021

Margaret A. Tempero et al.

Summary: Pancreatic cancer is the fourth leading cause of cancer-related death in the United States, with a major challenge being advanced disease at diagnosis. While survival rates have not significantly changed, newer treatments, including targeted therapies, offer hope for patients. The manuscript focuses on systemic therapy approaches for locally advanced and metastatic disease.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)

Article Gastroenterology & Hepatology

Practical Contribution of Virtual Hepatectomy for Colorectal Liver Metastases: a Propensity-Matched Analysis of Clinical Outcome

Takeshi Takamoto et al.

JOURNAL OF GASTROINTESTINAL SURGERY (2018)

Article Oncology

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. A. Eisenhauer et al.

EUROPEAN JOURNAL OF CANCER (2009)